Neogap Therapeutics selected for the Innovate Nordics 2025 Acceleration Program
Innovate Nordics targets Nordic growth companies aiming to establish a presence in the U.S. market
Neogap Therapeutics, a Swedish biotechnology start-up developing personalised immunotherapy for cancer treatment, announced that it has been selected for the Innovate Nordics 2025 Acceleration Program, organised by the Swedish-American Chamber of Commerce in New York (SACCNY) in partnership with EY.
Neogap Therapeutics
Innovate Nordics targets Nordic growth companies aiming to establish a presence in the U.S. market. Following a highly competitive selection process, Neogap was selected as one of the companies gaining access to market insights, business development support, and investor networks in the United States. The programme includes virtual workshops, a kick-off event in Stockholm, and a final Grand Pitch Finale in New York in May.
"We are honoured to have been selected for Innovate Nordics 2025. The programme offers us a valuable opportunity to strengthen existing relationships, build new ones, and increase our access to the U.S. market. Each step we take brings us closer to our goal – making personalised cancer immunotherapy available to more patients," says Andrea Salmén, COO at Neogap Therapeutics.
This spring, Neogap will take part in the programme's kick-off event on 8 May in Stockholm, followed by a delegation visit to New York from 19 to 21 May, where the company will present its work at the Grand Pitch Finale before investors and potential partners.
Neogap’s personalised immunotherapy, pTTL
Neogap is developing pTTL, a personalised, cell-based immunotherapy designed to enhance the patient’s own T cells to fight cancer. The therapy combines advanced DNA sequencing with T-cell expansion in a precision treatment for solid tumours and is based on Neogap’s proprietary technologies, PIOR® and EpiTCer®. The aim is to offer patients a tailored and innovative therapy that meets their specific needs.
Neogap recently announced positive initial safety observations from the first two patients treated in its ongoing Phase I/II trial for advanced colorectal cancer. The initial safety data indicate that the treatment is well tolerated, with no serious treatment-related adverse events observed.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.